MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.braindev.2023.08.004

Медицинская библиотека · Brain & development · 2023

Survey of medications for myelomeningocele patients over their lifetime in Japan.

Isozaki Haruna, Nonaka Masahiro, Komori Yumiko, Ueno Katsuya, Iwamura Haruka, Miyata Mayuko, Yamamura Natsumi, Li Yi, Takeda Junichi, Nonaka Yuichiro, Yabe Ichiro, Zaitsu Masayoshi, Nakashima Kenji, Asai Akio

СтатьяПеревод в очереди

Аннотация

BACKGROUND

This study aimed to investigate medication prescriptions for patients with myelomeningocele (MMC) across different age groups, particularly in adulthood and after middle age.

METHODS

The Japan Medical Data Center (JMDC) database, based on medical claims data, was utilized for this analysis. Patients were divided into 10-year age groups, and prescriptions for analgesics, anticonvulsants, psychotropic drugs, lifestyle disease-related drugs, drugs for urinary incontinence, and laxatives were examined. To compare the differences in the utilization of medications unrelated to lifestyle-related diseases across different age groups, the data was categorized into three age groups: 19 or under, 20-39, and 40 or older.

RESULTS

Among the 556 MMC patients, the percentage of those regularly prescribed analgesics increased from 2.8% in patients ≤ 19 to 31.7% in patients 40 or older (p < 0.01). Psychotropic medication use also increased with age, rising significantly from 6.3% in patients ≤ 19 to 34.6% in patients 40 or older (p < 0.01). Patients with MMC showed an increasing trend in prescriptions for lifestyle-related disease medications compared to the normal control group. Notably, the percentage of patients in their 30 s taking hypertension medication was 4.9%, significantly higher than the 0.86% in the control group (p = 0.029). In their 40 s, 22.9% of MMC patients were prescribed hyperlipidemia medication, significantly higher than the 3.9% in the control group (p < 0.01).

CONCLUSION

Comprehensive multidisciplinary support and follow-up are crucial to enhance the quality of life for MMC patients, with particular attention to pain management, psychological care, and treatment of lifestyle-related diseases.

Для цитирования: Isozaki Haruna, Nonaka Masahiro, Komori Yumiko, Ueno Katsuya, Iwamura Haruka, Miyata Mayuko, Yamamura Natsumi, Li Yi, Takeda Junichi, Nonaka Yuichiro, Yabe Ichiro, Zaitsu Masayoshi, Nakashima Kenji, Asai Akio. Survey of medications for myelomeningocele patients over their lifetime in Japan.. Brain & development. 2023. DOI: 10.1016/j.braindev.2023.08.004.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.